Argentum has particular success with its Silverlon Negative Pressure Dressing (NPD), which was the first antimicrobial silver dressing designed to be utilized with negative pressure wound therapy.

Argentum Medical chairman and CEO Gregg Silver said the most important thing to know is the trial has no impact on their patents and it is business as usual for Argentum.

"The case concerned non-patent issues and is currently being appealed. We are confident that our appeal will be successful," Silver said.

"The litigation will not affect our customers and will continue to provide our customers with Silverlon and our other products."